Assembly Biosciences (NASDAQ:ASMB) Issues Earnings Results

Assembly Biosciences (NASDAQ:ASMB) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.75) by $0.18, Zacks reports. The company had revenue of $7.36 million during the quarter, compared to the consensus estimate of $7.05 million. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%.

Assembly Biosciences Stock Up 2.2 %

Assembly Biosciences stock traded up $0.23 during midday trading on Friday, reaching $10.92. The stock had a trading volume of 24,311 shares, compared to its average volume of 24,426. Assembly Biosciences has a 1-year low of $10.27 and a 1-year high of $19.93. The firm’s fifty day simple moving average is $13.00 and its 200-day simple moving average is $15.18.

Insider Transactions at Assembly Biosciences

In related news, Director Michael Houghton bought 3,202 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average price of $15.61 per share, for a total transaction of $49,983.22. Following the completion of the acquisition, the director now owns 3,202 shares of the company’s stock, valued at approximately $49,983.22. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 5.10% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a research report on Friday, December 27th.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.